Abstract Details

Title Neurofilament Light Chain in the Clinic: Applications and Limitations in the Management of Multiple Sclerosis

Topic Multiple Sclerosis

Presentation(s) P6 - Poster Session 6 (5:00 PM-6:00 PM)

Poster/Presentation
Number 18-003

Objective To determine whether commercially obtained serum neurofilament light chain (NfL) levels were associated with MRI-based markers of multiple sclerosis (MS) progression and relapse.

Background Neurofilament light chain (NfL), a neuronal cytoskeletal protein, is a marker of active or recent axonal damage in various neurodegenerative disorders, including MS. Prior work has associated higher serum NfL levels with faster progression of MS as measured by the Expanded Disability Severity Scale (EDSS), highlighting its prognostic value.

Design/Methods We conducted an IT-based data extraction to review all serum NfL test results (Dec 2022-Jan 2025) commercially ordered by MS providers in our clinic (n=447). We then reviewed neuroimaging results from associated MRI procedures to determine whether a relapse had occurred close to the time of serum NfL testing. For our preliminary analysis, we reviewed available neuroimaging for all NfL results considered elevated according to commercial guidelines (n=28) and a random subsample of non-elevated results (n=30). Patients were then categorized as relapsing if new enhancing lesions were identified in radiology reports.

Results The mean NfL result for the relapsing group was greater than for non-relapsing, but not significantly (Two Sample t-test t = 1.7542, df = 56, p = .085). Similarly, a greater proportion of patients with elevated NfL results were relapsing, but the difference was not significant, X2 (1, N = 60) = 2.8, p = 0.092.

Conclusions Our borderline-significant results indicate that further investigation into the relationship between NfL and MS disease progression is needed. Thus far, NfL does not demonstrate the specificity required to replace neuroimaging in identifying relapses. However, it may be useful in identifying patients with subclinical progression that is undetectable on MRI. With further refinement of the interpretation of NfL, clinicians could use this test to identify patients who need changes in medication to slow disease progression.

Authors/Disclosures
Micah Hamilton PRESENTER	Mr. Hamilton has nothing to disclose.
Grace Inserra	Ms. Inserra has nothing to disclose.
Cate S. Ledoux	Miss Ledoux has nothing to disclose.
Nicholas S. Streicher, MD	Dr. Streicher has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion . Dr. Streicher has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Immunovent. Dr. Streicher has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Streicher has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Amgen. Dr. Streicher has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alexion.